LRRK2 is a large molecular machine involved in organizing materials inside cells. It is found in the brain as well as in immune cells, the lungs and the kidneys, where it performs functions that are not yet fully understood. The protein contains seven distinct domains, including regions that bind other cellular components and two enzymatic units. One of these enzymes is a kinase, which modifies target proteins by attaching phosphate groups to them. Excessive phosphorylation by LRRK2 is associated with Parkinson’s-related cellular dysfunction.

A second enzymatic region acts as a molecular switch by binding either GTP or GDP. In many cellular signaling proteins, GTP binding corresponds to an active state, while conversion of GTP to GDP helps return the protein to an inactive state. LRRK2, however, is controlled by a more intricate relationship between its switch and kinase domains. The Weill Cornell team set out to determine how these regions communicate and how their interaction controls access to the kinase’s active site.

Using cryo-electron microscopy alongside biochemical experiments, the researchers captured LRRK2 in a broad collection of structural states. They examined 16 different configurations, including molecules bound to GTP, molecules bound to GDP and molecules carrying neither nucleotide. These snapshots allowed the investigators to reconstruct the protein’s movements as it transitions between inactive and active forms, much like assembling a molecular film from individual frames.

The structures showed that GDP plays a central role in restraining LRRK2. When GDP is bound, LRRK2 adopts a compact conformation in which several domains fold toward one another and obstruct the kinase active site. This arrangement prevents the kinase from effectively contacting its protein targets. When GDP is released, the molecule undergoes a substantial rearrangement. Its domains move apart, exposing the active site and allowing the kinase to phosphorylate other proteins. Binding of GTP can then help stabilize this active configuration.

“This work provides a platform for identifying molecules that promote the formation of one configuration or the other,” said Dr. Samara Reck-Peterson, chair and professor of biochemistry and biophysics at Weill Cornell Medicine and an investigator at the Howard Hughes Medical Institute. Such compounds could allow researchers to control LRRK2 by influencing its overall shape rather than simply blocking the catalytic site. That approach may be especially valuable because LRRK2 carries out normal functions in several organs, making broad suppression potentially undesirable.

The structural data also clarified how Parkinson’s-associated mutations activate LRRK2 through different mechanisms. One well-known mutation occurs directly within the kinase domain and can increase the enzyme’s catalytic performance. Other mutations are located far from the kinase active site, including near the GTP-GDP switching machinery. Rather than making the kinase intrinsically faster, these distant mutations appear to increase the amount of time LRRK2 spends in its active conformation.

That distinction could have important consequences for treatment design. A drug that blocks the kinase’s catalytic pocket may work against mutations that directly enhance enzymatic activity, but it may not fully address mutations that alter the protein’s switching behavior. In the latter cases, an allosteric drug—one that binds at a regulatory site away from the active center—could potentially shift LRRK2 toward its inactive architecture. “Such allosteric drugs may offer greater precision and fewer side effects than conventional kinase inhibitors,” said Dr. Andres Leschziner, professor of biochemistry and biophysics at Weill Cornell and co-lead investigator.

The findings arrive as LRRK2 inhibitors and related compounds move through clinical testing, with at least four trials underway. The new structural blueprint could help medicinal chemists design therapies that selectively stabilize the off state or prevent disease-linked mutations from prolonging the on state. The study, led by Weill Cornell researchers with collaborators at the University of California, San Francisco, and Goethe University in Frankfurt, was co-first-authored by graduate students Amalia Villagran Suarez and Kathryn Hatch. By showing precisely how LRRK2’s domains cooperate to control its activity, the work brings researchers closer to mutation-specific strategies for slowing Parkinson’s disease while preserving the protein’s normal biological roles.

Subject of Research: LRRK2 protein activation and autoinhibition in Parkinson’s disease

Article Title: The structural basis for LRRK2’s activation and autoinhibition

News Publication Date: 10-Aug-2026

Web References: https://doi.org/10.1016/j.cell.2026.07.027; https://vivo.weill.cornell.edu/display/cwid-slr4003; https://vivo.weill.cornell.edu/display/cwid-ale4009

References: Cell, DOI: 10.1016/j.cell.2026.07.027

Image Credits: Weill Cornell Medicine

Keywords: Parkinson’s disease, LRRK2, protein structure, cryo-electron microscopy, kinase activity, GTP-GDP switch, molecular biology, allosteric drugs, neurodegenerative disease, biomedical research

Parkinson’s disease afflicts millions globally, characterized by motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. These clinical features arise primarily from the degeneration of neurons responsible for producing dopamine, a critical neurotransmitter involved in movement control. Despite years of research, the precise genetic and molecular pathways driving neuronal downfall remain only partially understood. Among several genetic contributors, mutations in the ATP13A2 gene have been identified in familial cases presenting with early-onset parkinsonism and atypical symptoms.

The ATP13A2 gene encodes a lysosomal P-type ATPase implicated in cation transport and lysosomal function, critical to maintaining neuronal health by managing cellular waste and metal ion homeostasis. Mutations in ATP13A2 are known to cause Kufor-Rakeb syndrome, a rare hereditary form of PD with prominent neurodegeneration. However, the exact consequences of ATP13A2 deficiency in a living organism have not been extensively modeled, especially in species with closer physiological relevance to humans such as rats.

By generating an Atp13a2 knockout rat using cutting-edge CRISPR-Cas9 gene editing technology, researchers have engineered a biologically pertinent model that simulates the genetic deficit observed in human pathology. This model allows for comprehensive behavioral, histological, and biochemical assessments to flesh out the phenotypic repercussions of Atp13a2 loss. The results reveal that absence of functional Atp13a2 induces a spectrum of Parkinsonian-like traits, mirroring many features seen in human patients, thereby validating the model’s utility.

Behavioral examinations of the Atp13a2 KO rats uncovered disturbances consistent with Parkinson’s disease symptomatology. The mutant rats manifested progressive motor deficits, including reduced spontaneous movement, impaired coordination, and gait abnormalities. These phenotypic alterations escalated with age, paralleling the chronic nature of PD progression in humans. The pronounced motor dysfunction reinforces the gene’s crucial role in sustaining normal neural circuitry involved in motor control.

At a cellular level, detailed neuroanatomical analyses disclosed a significant degeneration of dopaminergic neurons within the substantia nigra pars compacta, the hallmark of Parkinson’s neuropathology. Immunohistochemical staining showed diminished expression of tyrosine hydroxylase – a key enzymatic marker for dopamine synthesis – underscoring the impact of Atp13a2 deletion on dopamine-producing cells. Moreover, increased gliosis indicated reactive inflammation, an additional factor contributing to neurodegeneration.

The study also delved into lysosomal and mitochondrial integrity, revealing that Atp13a2 deficiency impairs cellular organelle function, critical components implicated in PD. Lysosomal dysfunction was evident, aligning with the gene’s known role in lysosomal homeostasis, causing defective clearance of misfolded proteins and damaged organelles. This accumulation potentially triggers neurotoxicity and cell death pathways. Mitochondrial abnormalities further exacerbate cellular stress, compounding neuronal vulnerability.

Of particular interest was the examination of alpha-synuclein, a protein famously associated with Lewy bodies in PD. The Atp13a2 KO rats exhibited abnormal aggregations of alpha-synuclein within affected brain regions, reinforcing the link between Atp13a2 function and protein aggregation processes. This pathogenic cascade reflects a crucial aspect of PD etiology, providing new insights into how genetic mutations can perturb fundamental proteostasis mechanisms leading to neuronal demise.

In addition to central nervous system pathology, the model revealed systemic manifestations, including altered peripheral metabolism and immune responses. These findings underscore the multifactorial nature of Parkinson’s disease extending beyond the brain, opening avenues for holistic disease understanding and treatment development. The integrative phenotyping performed on this model establishes comprehensive groundwork for future studies dissecting the interplay between various systemic contributors to PD.

Importantly, this Atp13a2 knockout rat model offers a robust and reproducible platform for preclinical testing of novel therapeutics aimed at halting or reversing PD progression. Current treatments primarily address symptoms and fail to decelerate neurodegeneration. By closely mimicking human genetic and pathological features, this model enables targeted investigation of drugs designed to restore lysosomal function, mitigate alpha-synuclein pathology, or protect mitochondrial health—ultimately striving for disease-modifying therapies.

The relevance of this model extends to precision medicine as well. Understanding patient-specific genetic backgrounds and molecular pathways may tailor treatment strategies more effectively. The characterization of Atp13a2-deficient rats enriches the resource pool for studying gene-environment interactions, epigenetic modifications, and compensatory mechanisms, pivotal for identifying personalized markers and interventions.

In conclusion, establishing and characterizing the Atp13a2 knockout rat significantly advances the neurodegeneration field, bridging a crucial gap between genetic insights and translational research. By elucidating how ATP13A2 mutations drive Parkinsonian pathology, this study propels the scientific community closer to unraveling disease complexities and developing efficacious interventions. As Parkinson’s disease continues to impose a substantial burden on patients and healthcare systems worldwide, innovative models like this provide hope for breakthroughs that could change clinical landscapes.

The meticulous phenotypic profiling of Atp13a2 KO rats underlines the critical importance of lysosomal ATPases in neuronal survival and function, offering a fresh perspective on therapeutic targets in PD. Future explorations leveraging this model have the potential to unravel novel molecular players and pathways, fostering the emergence of next-generation neuroprotective agents. This pioneering research sets a new benchmark for genetic modeling of neurodegenerative diseases, underscoring the indispensable synergy between advanced gene-editing methodologies and comprehensive phenotypic analysis.

As the scientific community embraces such innovative models, there is optimism that unraveling the mysteries of Parkinson’s disease will accelerate, ultimately translating into tangible benefits for patients. Continuous interdisciplinary collaboration and integrative approaches will be key to harnessing the full potential of this Atp13a2-deficient rat model, spotlighting it as a transformative tool in the relentless quest to conquer Parkinson’s disease.

Subject of Research: Parkinson’s disease and the phenotypic characterization of an Atp13a2 knockout rat model.

Article Title: Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson’s disease.

Article References:
Kinet, R., Sikora, J., Arotcarena, ML. et al. Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson’s disease. npj Parkinsons Dis. 11, 321 (2025). https://doi.org/10.1038/s41531-025-01171-0